 | Up a level |
Griesinger, F., Radke, S., Lueers, A., Deschler-Baier, B., Kimmich, M., Sebastian, M., Schulz, C., Brugger, W., Wiewrodt, R., Pirker, R., Fruh, M., Gautschi, O. and Wolf, J. (2018). Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example. Pneumologie, 72 (11). S. 774 - 782. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262